Dalpiciclib Plus Letrozole and Capecitabine
to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with breast cancer
Advanced Breast Cancer
DRUG: Dalpiciclib+ letrozole +capecitabine
ORR, Objective response rate, 24 month
CBR, Clinical Benefit Rate, 24 month
The purpose of the study is to assess the effect of dalpiciclib plus letrozole and capecitabine of first-line treatment with high-risk for HR- positive /HER-2 negative advanced breast cancer